source
- Astellas secures exclusive option on Audax Biosciences preclinical IL-12 cancer drugAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Audax Biosciences, an Australian biotech company. The asset is an IL-12 based cancer therapeutic that is…
- Lawmaker asks GAO to examine TrumpRx claims of $700 million drug savingsRepresentative Frank Pallone, the ranking member of the House Energy and Commerce Committee, sent a letter to the Government Accountability Office asking it to assess whether the TrumpRx website ha…